Inactive Instrument

Mologen AG

Equities

MGNK

DE000A2LQ900

Biotechnology & Medical Research

Mologen AG Supports Development Strategy of lefitolimod (MGN1703)

February 25, 2016 at 03:22 am EST

Mologen AG announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has confirmed the development strategy of lefitolimod (MGN1703) with the pivotal IMPALA study by scientific advice.

Latest news about Mologen AG

Mologen AG Announces Updates on Phase III IMPALA Study; Provides Earnings Guidance for the Full Year 2019	19-08-14	CI
Mologen AG Announces Management Changes	19-03-27	CI
Mologen AG Announces Management Changes	18-08-01	CI
Mariola Soehngen Not to Renew Her Position as Member and Chief Executive Officer on the Board of Directors of Mologen AG Which Expires on 31 October 2018	18-04-20	CI
Mologen Reports Earnings Results for the Six Months of 2016; Provides Earnings Guidance for the Full Year of 2016	16-08-17	CI
Mologen AG Announces Progress in Clinical Studies; Announces Earnings Results for the First Quarter of 2016; Confirms Earnings Guidance for the Year 2016	16-05-12	CI
Mologen AG Reports Earnings Results for the Year 2015	16-03-21	CI
MOLOGEN AG Appoints Walter Miller as Member of the Executive Board and Chief Financial Officer with Effect from April 1, 2016	16-03-16	CI
Mologen AG Announces Extension of TEACH Study Based on Supportive First Study Results	16-03-14	CI
Mologen AG Supports Development Strategy of lefitolimod (MGN1703)	16-02-25	CI
MOLOGEN AG and the University of Texas MD Anderson Cancer Center Enter into Collaboration Agreement Relating to Phase I trial with MOLOGEN’s Immunomodulator Lefitolimod in Combination with the Immunotherapy Yervoy® in Patients with Advanced Solid Malignancies	16-01-19	CI
MOLOGEN AG Reaffirms Earnings Guidance Financial Year 2015	15-11-12	CI
Mologen AG(XTRA:MGN) dropped from S&P Global BMI Index	15-09-21	CI
Mologen AG Reports Earnings Results for the First Half of 2015	15-08-13	CI
MOLOGEN AG Announces Managements Changes	15-07-23	CI
Mologen Holding AG’s Equity Buyback announced on June 7, 2010 has expired.	15-06-06	CI
Aarhus University Hospital Initiates MGN1703 Study in HIV Patients	15-05-08	CI
MOLOGEN AG Presents Data Supporting Administration Scheme of MGN1703 at ITOC-2 Conference 2015	15-03-30	CI
Mologen Reports Earnings Results for the Year 2014	15-03-25	CI
Mologen AG Presents Subgroup Analysis from Impact Study and Design of Pivotal Impala Trial	15-01-19	CI
Mologen AG Provides Earnings Guidance for the Year of 2014; Announces Results of Clinical Development of the Cancer Immunotherapy MGN1703	14-11-13	CI
MOLOGEN Presents Preclinical Data on its EnanDIM Technology at 10th Annual Meeting of the Oligonucleotide Therapeutics Society	14-10-14	CI
Mologen AG Announces Initiation of Phase III IMPALA Study with Immunotherapy MGN1703 in Colorectal Cancer	14-09-11	CI
Mologen AG Receives First Approvals for Phase III Impala Colorectal Cancer Study	14-08-04	CI
Mologen AG Presents Immunological Data on Renal Cancer Therapy MGN1601 at CIMT	14-05-07	CI

Chart Mologen AG

Duration

Period

More charts

Company Profile

Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research